trial · primary record
olaparib
Epithelial Ovarian Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2028-06 |
| Primary endpoint | Feasibility of the WoO procedure for olaparib alone (cohort a) & olaparib in combination with durvalumab (cohort b) |
| Registry ID | NCT04644289 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:25.343Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04644289
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.